Fluorescence in situ hybridization (FISH) in the diagnosis of bladder and upper tract urothelial carcinoma: the largest single-institution experience to date
Leonard G. Gomella, Mark J. Mann, Ryan C. Cleary, Scott G. Hubosky, Demetrius H. Bagley, Adeep B. Thumar, Peter A. McCue, Costas D. Lallas, Edouard J. Trabulsi
Canadian Journal of Urology, Vol.24, No.1, pp. 8620-8626, 2017
Abstract Introduction: We evaluated the UroVysion (Abbott Molecular, IL, USA) fluorescence in situ hybridization (FISH) assay for the diagnosis of urothelial cancer in patients diagnosed with or suspected to have bladder, upper tract urothelial carcinoma (UTUC), and combined upper and lower tract urothelial carcinoma (BC).
Materials and methods: A single institution retrospective analysis comparing sensitivity, specificity, positive predictive value, and negative predictive values for FISH and urinary cytology. FISH within 6 months of endoscopic evaluation were obtained from outpatient voided urine samples. Our institutional pathology department confirmed pathologic disease from specimens obtained during endoscopic evaluations for lower tract… More >